Efficacy of Faricimab in the Treatment of Diabetic Macular Edema and Faricimab-Related Changes in OCT and OCT Angiography.

Longitudinal Evaluation of CRT over Four Months of Faricimab Therapy The linear mixed-effects model revealed substantial reductions in central retinal thickness compared to baseline, with highly significant improvements observed at one month (β = −115.86, 95% CI : −143.36–−88.36, p < 0.001), two months (β = −147.83, 95% CI : −175.33–−120.32, p < 0.001), three months (β = −175.76, 95% CI : −203.26–−148.26, p < 0.001), and four months (β = −183.50, 95% CI : −211.00–−156.00, p < 0.001).

also in 36,814 other papers

Changes in CCFA showed a marginally nonsignificant increase at one month (β = 0.97, 95% CI: −0.05–1.98, p = 0.062), which then reached statistical significance by the second month (β = 1.33, 95% CI: 0.31–2.35, p = 0.011), with a marked increase at three months (β = 2.85, 95% CI: 1.84–3.87, p < 0.001) and four months (β = 3.86, 95% CI: 2.84–4.88, p < 0.001).

also in 126 other papers

The estimated change (β = −0.21, 95% CI : −0.57–0.14, p = 0.241) did not reach statistical significance one month post-baseline.

also in 39,124 other papers